Unichem plans Rs 350 crore capex for next two years

09 Jun 2017 Evaluate

In order to strengthen its R&D activity and expand operations in the US market, Unichem Laboratories has lined up capex of around Rs 350 crore for the next two years. The company, which focuses on various therapeutic segments like gastroenterology and cardiology, expects its US revenues to cross $100 million over the next few years. The long term aim of the company is to cross $500 million in revenues from the US operations.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Lab Share Price

431.00 -11.70 (-2.64%)
30-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.80
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 902.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×